Daratumumab Dosing Schedule for Multiple Myeloma
Daratumumab is administered at 16 mg/kg intravenously with a step-down dosing schedule: weekly for 8 weeks (or 6-9 weeks depending on regimen), then every 2 weeks for 16 weeks, then every 4 weeks until disease progression. 1
Standard Dosing Schedules by Regimen
For Combination with Lenalidomide/Dexamethasone (DRd) or Pomalidomide/Dexamethasone (DPd)
The dosing follows a 4-week cycle regimen 1:
- Weeks 1-8: Weekly administration (total of 8 doses) 2, 1
- Weeks 9-24: Every 2 weeks (total of 8 doses) 2, 1
- Week 25 onwards: Every 4 weeks until disease progression 2, 1
This schedule applies to both newly diagnosed patients ineligible for autologous stem cell transplant and relapsed/refractory patients 1.
For Combination with Bortezomib/Dexamethasone (DVd)
The dosing follows a 3-week cycle regimen 1:
- Weeks 1-9: Weekly administration (total of 9 doses) 2, 1
- Weeks 10-24: Every 3 weeks (total of 5 doses) 2, 1
- Week 25 onwards: Every 4 weeks until disease progression 2, 1
For Combination with Bortezomib/Melphalan/Prednisone (D-VMP)
The dosing follows a 6-week cycle regimen 1:
- Weeks 1-6: Weekly administration (total of 6 doses) 1
- Weeks 7-54: Every 3 weeks (total of 16 doses) 1
- Week 55 onwards: Every 4 weeks until disease progression 1
For Combination with Carfilzomib/Dexamethasone (DKd)
This regimen has a unique first-week dosing 1:
- Week 1: 8 mg/kg on days 1 and 2 (split first dose, total 2 doses) 1
- Weeks 2-8: 16 mg/kg weekly (total of 7 doses) 1
- Weeks 9-24: 16 mg/kg every 2 weeks (total of 8 doses) 1
- Week 25 onwards: 16 mg/kg every 4 weeks until disease progression 1
Monotherapy Dosing
For patients who have received at least 3 prior lines of therapy, daratumumab monotherapy follows the same schedule as the DRd/DPd regimen 2, 1:
Infusion Duration Considerations
The first infusion takes approximately 6.5 hours, while subsequent infusions take approximately 3.5 hours 2. Infusion-related reactions occur predominantly during the first infusion (56-92% of patients) and are mostly grade 1-2 2. The split first-dose approach (8 mg/kg on days 1 and 2) reduces infusion-related reactions from 60% to 43% compared to single dosing 3.
Clinical Rationale for Step-Down Dosing
The pharmacokinetic rationale for this schedule is to rapidly saturate target-mediated clearance during the intensive weekly phase, then maintain CD38 target saturation with less frequent dosing 4. Daratumumab exhibits nonlinear pharmacokinetics with decreasing clearance over time as CD38-positive myeloma cells are eliminated 4. Steady state is achieved approximately 5 months into the every-4-week dosing period 1.
Important Caveats
- Pre-infusion and post-infusion medications are required to prevent infusion-related reactions 1
- Type and screen patients prior to starting therapy due to interference with blood bank testing 1
- The subcutaneous formulation (1800 mg fixed dose) offers an alternative with shorter administration time (3-5 minutes) and lower infusion-related reaction rates 5
- No dose adjustments are needed based on age, sex, renal impairment (CrCl 15-89 mL/min), or mild-to-moderate hepatic impairment 1